About Us

Taylor is a co-founder of Shattuck Labs and currently serves as Chief Executive Officer and a member of the Board of Directors. Before his appointment as CEO in January 2020, Taylor served as the company’s Chief Scientific Officer. Taylor has published extensively on the TL1A/DR3 axis, and created a number of the key reagents used by the field today while studying with Dr. Eckhard Podack at the University of Miami. Prior to Shattuck, he served as Chief Scientific Officer of Heat Biologics, Inc. where he was a co-inventor of significant elements of Heat’s ImPACT and ComPACT technology platforms. Taylor has numerous publications in the field of tumor immunology and immunotherapy, spanning the subjects of cancer vaccines, therapeutic proteins and antibodies, adenosinergic and IDO mediated immunosuppression and regulatory T cell biology. Taylor received both his M.D. and Ph.D. degrees from the Sheila and David Fuente Program in Cancer Biology at the University of Miami Miller School of Medicine. He received his B.A. in Biology from Bucknell University.

Lini joined Shattuck Labs in July 2017 as Chief Medical Officer. She brings more than 25 years of academic, medical, and pharmaceutical experience. Her broad oncology drug development expertise spans early-to-late phase development from Pre-IND through registration and commercialization. Prior to joining Shattuck, Lini was Head of Global Clinical Development and Senior Vice President at Adaptimmune, responsible for clinical development of the company’s immuno-oncology pipeline. She spent several years with GlaxoSmithKline (GSK) culminating her tenure as, Vice President R&D and Head Unit Physician for Oncology. While at GSK, Lini was instrumental in leading the development of several compounds. Lini practiced medicine in both the United Kingdom and the United States and is Board Certified in Hematology and Oncology. Lini was an attending physician at Dana Farber Cancer Institute in Boston and at Sylvester Comprehensive Cancer Center/Jackson Memorial Hospital in Miami and held academic appointments at Harvard University and the University of Miami. She received her medical degree from The University of Liverpool, England and a Master’s in Business Administration from the Fuqua School of Business at Duke University.

Casi joined Shattuck in December of 2019. She brings a background in management consulting and over twenty years in the healthcare and life science industries. She has held leadership roles in five US start-up businesses (private and public). Most recently Casi served as Chief Operating Officer for ImmuneSensor Therapeutics where she was responsible for corporate strategy, start-up operations, intellectual property, oversight of the company’s first IND filing and the initiation of a first-in-human Phase 1 clinical trial. Previously, she held leadership positions including Chief Business Officer at Mirna Therapeutics, Vice President of Business Development at Reata Pharmaceuticals, Vice President of Business Development at ODC Therapy and Operations Director for Oncology at EMD Pharmaceuticals and Merck KGaA. Casi earned a B.S. in Chemistry, from Southwestern University and an M.B.A. from the McCombs School of Business at the University of Texas at Austin.

Andrew has served as our Chief Financial Officer since March 2021. He previously served as our Vice President of Finance and Corporate Strategy from July 2020 to March 2021 and as our Vice President of Corporate Development and Strategy from May 2017 to July 2020. Andrew joined Shattuck Labs in 2017 and brings over 15 years of biotechnology company management experience. Previously, Andrew was the co-founder of Lumos Pharma, a biopharmaceutical company focused on developing therapeutics for genetic rare diseases. Andrew holds an M.B.A, with majors in Health Care Management and Finance, from The Wharton School at the University of Pennsylvania, where he was a Kaiser Fellow. Andrew holds a Bachelor of Business Administration from Texas Christian University.

Dr. Shukla joined Shattuck in June of 2021 as Chief Technical Officer. He brings a background of demonstrated leadership across the full spectrum of biologics process development and manufacturing to Shattuck. Most recently Dr. Shukla served as the Chief Technical Operations Officer at Redpin Therapeutics, where he was responsible for all aspects of process, analytical and formulation development, and cGMP manufacturing. Previously, he held several senior leadership positions, including Vice President of Manufacturing at CRISPR Therapeutics, Vice President and Head of Biologics Process Development at Shire, Senior Vice President of Process Development and Manufacturing at KBI Biopharma, and in senior scientific roles at Bristol-Myers Squibb and Amgen prior to KBI. Throughout his career, Dr. Shukla has been involved in over 75 investigational new drug applications as well as the commercialization of several therapeutics, including Yervoy®, Orencia®, and Nulojix®. Dr. Shukla received his doctorate in Chemical and Biochemical Engineering from Rensselaer Polytechnic Institute and his undergraduate degree from the Indian Institute of Technology, Delhi.

Suresh has served as our Chief Scientific Officer since January 2023. He served as Vice President of Product Development from 2018-2022 and our Executive Director of Research and Development from 2017-2018. Suresh joined Shattuck in 2017 and is one of the scientific co-inventors of the ARC technology platform and co-led the preclinical development of SL-279252 and SL-172154. Prior to joining Shattuck, Suresh served as the Director of Research and Development at Heat Biologics, Inc. in Durham, NC, where he led external research collaborations and co-developed the ComPact cell-based vaccine platform. Suresh’s research experience spans the fields of gene therapy, infectious disease (HIV), and cancer immunotherapy, where he has co-authored numerous publications in lead journals such as Cancer Immunology Research, Nature Medicine, Human Gene Therapy, and the Journal of Biological Chemistry. Suresh has also co-authored several successful federal grant applications, including two R01’s awarded from the National Institute of Allergy and Infectious Diseases (NIAID) and an R21 that was received from the National Cancer Institute (NCI). Suresh received his M.S. and Ph.D. from the University of Rochester, NY, and subsequently completed a successful post-doctoral fellowship at The Ohio State University, where he was a recipient of a Staff Career Development Grant from their College of Veterinary Medicine.

Stephen serves as Shattuck’s General Counsel, Corporate Secretary and Chief Ethics and Compliance Officer. He joined Shattuck in 2021 after spending nearly 15 years in private practice with Vinson & Elkins L.L.P. and Baker Botts L.L.P. Stephen’s practice focused on federal litigation, particularly in intellectual property and technology disputes involving the life sciences and digital media. Stephen has a J.D., with honors, from the University of Texas School of Law, a Ph.D. from the University of Texas at Austin, an M.S. from Louisiana State University, and a B.S. from Texas A&M University. He is admitted to practice law in Texas and before the U.S. Patent & Trademark Office. He is also a longtime author of the annually updated O’Connor’s Federal Intellectual Property Codes Plus and an adjunct professor with the trial advocacy program at the University of Texas School of Law.

Kelli has served as our Senior Vice President of Quality since January 2023. She joined Shattuck in January 2021 as Vice President of Quality. Prior to joining Shattuck, Kelli was the Executive Director of Quality Assurance at Liquidia Technologies, leading the quality department for GMP, GCP, and GLP operations. Kelli has over 20 years of experience in quality assurance, covering all aspects of the pharmaceutical product lifecycle. She received her Bachelor’s degree in Biological Engineering and a Master of Bioinformatics from North Carolina State University. She received her Master’s in Business Administration with a concentration in Supply Chain Management from the Cameron School of Business at the University of North Carolina at Wilmington. She also holds a graduate certificate in Pharmaceutical & Medical Device Law & Compliance from Seton Hall Law School. She is a Certified Quality Manager/Operational Excellence (CMQOE) and a Certified Pharmaceutical GMP Professional (CPGMPP).

Thomas joined Shattuck in April 2018 as Head of Regulatory Affairs. He has more than 22 years of experience at GlaxoSmithKline, most recently as a Senior Director in Global Regulatory Affairs responsible for regulatory strategy and leading regulatory teams for global and US focused programs. Prior to regulatory affairs, Thomas was a Senior Director within oncology clinical development at GSK, leading global clinical development teams for multiple solid tumor and hematologic malignancy programs. In both regulatory and clinical roles, he has experience spanning drug development from prior to candidate selection through approval to market. Thomas was previously a co-founder and Director of the Clinical Research Center at Sarasota Memorial Hospital in Florida, an Assistant Director in the Department of Pharmaceutical Services, and Coordinator of the Institutional Review Board. Thomas has a Doctor of Pharmacy degree from University of Illinois at Chicago, and completed a Fellowship in Clinical Research and Drug Development at The University of North Carolina at Chapel Hill.

Michael joined Shattuck Labs as Vice President of Clinical Development in 2025. Prior to Shattuck, he was the clinical lead at Morphic Therapeutic where he spearheaded the design and execution of multiple phase 2 inflammatory bowel disease trials—work that played a central role in the company’s acquisition by Eli Lilly in 2024. At Lilly, he continued work in immunology space by supporting two phase 3 studies and in-licensing diligence. Michael has played a role in biotech innovation as Co-Founder and Scientific Advisor at Mediar Therapeutics, helping the company raise more than $170 million and secure a major licensing partnership with Eli Lilly. He also advised in starting and growth of Iterative Health as its first clinical advisor. Earlier in his career, Michael served as Assistant Professor of Medicine at Harvard Medical School and Affiliated Faculty at the Harvard Stem Cell Institute, leading a research lab focused on liver fibrosis and cell reprogramming. Michael received his medical degree from Cornell, trained in Internal Medicine at UCSF, and completed his Gastroenterology Fellowship at Massachusetts General Hospital.

Amy joined Shattuck in October 2022 as Vice President of Clinical Operations. She brings over 25 years of drug development experience, including over 20 years in oncology clinical development. Prior to joining Shattuck, Amy was the Vice President of Clinical Operations at Aravive and NervGen Pharma. Her prior experience also includes multiple CROs and biotech companies, including OSI Pharmaceuticals, where Amy was the Clinical Operations lead for an IGF-1R inhibitor program. She has contributed to the conduct of dozens of clinical trials, ranging from Phase I to Phase III. Amy completed her BS in Cellular and Molecular Biology at the University of Michigan and later achieved a master’s degree in Bioethics from the University of Pennsylvania.